Allarity Therapeutics, Inc. (ALLR)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-04-01) · 99.1 | ||
| 10-KLatest | FY-2025 | — | ||
| 10-Q | Q3-2025 | — | ||
| 10-Q | Q2-2025 | — | ||
| 10-Q | Q1-2025 | 8-K (2025-05-09) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-31) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-14) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-05-15) · 99.1 | ||
| 10-Q | Q1-2024 | — | ||
| 10-K/A | FY-2023 | |||
| 10-K | FY-2023 | 8-K (2024-03-08) · 99.1 | ||
| 10-Q | Q3-2023 | — | ||
| 10-Q | Q2-2023 | — |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Document and Entity Information | ||
| Audit Information | — |
|
| Statements | ||
| Condensed Consolidated Balance Sheets (current Period Unaudited) | — |
|
| Consolidated Balance Sheets | ||
| Condensed Consolidated Balance Sheets (current Period Unaudited) (P) | — |
|
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Changes In Redeemable Convertible Stockholders' Equity (deficit) (unaudited) | — |
|
| Condensed Consolidated Statements of Changes In Stockholders' Equity (deficit) (unaudited) | — |
|
| Consolidated Statements of Changes In Redeemable Convertible Preferred Stock and Stockholders' Equity (deficit) | ||
| Consolidated Statements of Operations and Comprehensive Loss (P) | ||
| Condensed Consolidated Statements of Changes In Redeemable Convertible Stockholders' Equity (deficit) (unaudited) (P) | — |
|
| Condensed Consolidated Statements of Changes In Redeemable Preferred Stock and Stockholders Equity (deficit) (unaudited) | — |
|
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Changes In Redeemable Convertible Preferred Stock and Stockholders' Equity (deficit) (P) | ||
| Condensed Consolidated Statements of Cash Flows (unaudited) (P) | — |
|
| Condensed Consolidated Statements of Changes In Redeemable Preferred Stock and Stockholders Equity (deficit) (unaudited) (P) | — |
|
| Notes | ||
| Accrued Liabilities | ||
| Award Timing Disclosure | — |
|
| Basic and Diluted Net Loss Per Share | — |
|
| Commitments and Contingencies | ||
| Convertible Debt | — |
|
| Convertible Promissory Note and Accrued Interest, Net | ||
| Convertible Promissory Note Due To Novartis | — |
|
| Convertible Senior Promissory Notes Due To 3i, Lp (3i) | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Derivative Liabilities | ||
| Financial Instruments | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Intangible Assets | ||
| License and Development Agreements | ||
| Loss Per Share of Common Stock | — |
|
| Note 1 | ||
| Note 10 | ||
| Note 11 | ||
| Note 12 | ||
| Note 13 | ||
| Note 14 | ||
| Note 15 | ||
| Note 16 | — |
|
| Note 17 | — |
|
| Note 2 | ||
| Note 3 | ||
| Note 4 | ||
| Note 5 | ||
| Note 6 | ||
| Note 7 | ||
| Note 8 | ||
| Note 9 | ||
| Organization, Principal Activities and Basis of Presentation | — |
|
| Organization, Principal Activities, and Basis of Presentation | ||
| Other Current Assets | ||
| Pay Vs Performance Disclosure | ||
| Preferred Stock | ||
| Related Parties | — |
|
| Related Party | — |
|
| Secured Promissory Notes | — |
|
| Segments | — |
|
| Share-based Payments | — |
|
| Stock-based Payment Plan and Stock-based Payments | — |
|
| Stock-based Payments | — |
|
| Stockholders Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| Tax | — |
|